Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.
Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr. Sagae S, et al. Among authors: backes fj. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Int J Gynecol Cancer. 2014. PMID: 25341586 Review.
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.
O'Malley DM, Myers T, Wimberger P, Gorp TV, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. O'Malley DM, et al. Among authors: backes fj. Future Oncol. 2024 Jul 31:1-14. doi: 10.1080/14796694.2024.2372241. Online ahead of print. Future Oncol. 2024. PMID: 39082675
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gien LT, Enserro DM, Block MS, Waggoner S, Duska LR, Wahner-Hendrickson AE, Thaker PH, Backes F, Kidd M, Muller CY, DiSilvestro PA, Covens A, Gershenson DM, Moore KN, Aghajanian C, Coleman RL. Gien LT, et al. Gynecol Oncol. 2024 Jul;186:61-68. doi: 10.1016/j.ygyno.2024.03.027. Epub 2024 Apr 10. Gynecol Oncol. 2024. PMID: 38603953 Clinical Trial.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE. Praiss AM, et al. Gynecol Oncol. 2023 Jul;174:213-223. doi: 10.1016/j.ygyno.2023.05.013. Epub 2023 May 23. Gynecol Oncol. 2023. PMID: 37229879 Free PMC article. Clinical Trial.
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Brown J, et al. Gynecol Oncol. 2024 Sep 11;190:283-290. doi: 10.1016/j.ygyno.2024.09.002. Online ahead of print. Gynecol Oncol. 2024. PMID: 39265466
The impact of body weight on ovarian cancer outcomes.
Backes FJ, Nagel CI, Bussewitz E, Donner J, Hade E, Salani R. Backes FJ, et al. Int J Gynecol Cancer. 2011 Dec;21(9):1601-5. doi: 10.1097/IGC.0b013e31822d2aa3. Int J Gynecol Cancer. 2011. PMID: 21997171 Free PMC article.
151 results